Zobrazeno 1 - 10
of 502
pro vyhledávání: '"Pharmacogenetic testing"'
Publikováno v:
BMC Psychiatry, Vol 24, Iss 1, Pp 1-5 (2024)
Abstract Background Strong evidence for therapeutic drug monitoring exists for olanzapine and clozapine, however, olanzapine therapeutic drug monitoring is often underutilized. Evidence for pharmacogenomic-guided dosing of antipsychotics is not as ro
Externí odkaz:
https://doaj.org/article/6200b565a5c24ebfb2e72bf7b97e7b5c
Publikováno v:
Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki, Vol 17, Iss 3, Pp 291-296 (2024)
Aim. The purpose of this work is to emphasize the importance and practical benefits of pharmacogenetics in medicine, demonstrating how the integration of pharmacogenetics into clinical practice can improve treatment outcomes and enhance the safety of
Externí odkaz:
https://doaj.org/article/b811d12900c1467f916385bc0d630c12
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
IntroductionIncreasingly, pharmacogenetic testing helps providers with medication selection based upon patient-specific DNA results. While several government-funded organizations work towards consensus and standardization for testing and interpretati
Externí odkaz:
https://doaj.org/article/1c8971a5fd0241c29e3ffc2165c85fa0
Publikováno v:
Безопасность и риск фармакотерапии, Vol 12, Iss 2, Pp 132-154 (2024)
INTRODUCTION. Pharmacogenetic (PGx) testing plays a significant role in predicting the risk of adverse drug reactions (ADRs) associated with valproic acid (VPA) products, which are among the most prescribed medicinal products in neurology and psychia
Externí odkaz:
https://doaj.org/article/32c6ea0e49e5483e87a4e211daaad892
Autor:
A. S. Zhiryakova, N. P. Denisenko, A. V. Kryukov, K. A. Akmalova, S. N. Tuchkova, K. B. Mirzaev, D. A. Sychev
Publikováno v:
Безопасность и риск фармакотерапии, Vol 12, Iss 2, Pp 178-189 (2024)
INTRODUCTION. The variability in patient response to non-steroidal anti-inflammatory drugs (NSAIDs) may be due to genetic polymorphisms. Decreased-function or non-functional CYP2C9 alleles are known to be significant contributors to response variabil
Externí odkaz:
https://doaj.org/article/ce69b2b2c49b44658781ec122244b276
Autor:
Sireen Abdul Rahim Shilbayeh, Iman Sharaf Adeen, Ezzeldeen Hasan Ghanem, Haya Aljurayb, Khawlah Essa Aldilaijan, Fatimah AlDosari, Abeer Fadda
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
Background: Autism spectrum disorders (ASDs) encompass a broad range of phenotypes characterized by diverse neurological alterations. Genomic studies have revealed considerable overlap between the molecular mechanisms implicated in the etiology of AS
Externí odkaz:
https://doaj.org/article/09cc4a66b53c4ea5b893a2a8e4cce094
Autor:
Ling Jing Li, Samuel Legeay, Ann-Lorie Gagnon, Marie-Pier Frigon, Laurence Tessier, Karine Tremblay
Publikováno v:
Frontiers in Genetics, Vol 14 (2024)
Clinical implementation of pharmacogenetics (PGx) into routine care will elevate the current paradigm of treatment decisions. However, while PGx tests are increasingly becoming reliable and affordable, several barriers have limited their widespread u
Externí odkaz:
https://doaj.org/article/9753029b7c284468985ed4e9216ada15
Publikováno v:
Pharmacogenomics and Personalized Medicine, Vol Volume 16, Pp 503-518 (2023)
Shimaa Aboelbaha,1 Monica Zolezzi,2 Oraib Abdallah,3 Yassin Eltorki3 1College of Pharmacy, QU Health, Qatar University, Doha, Qatar; 2Clinical Pharmacy and Practice, College of Pharmacy, QU Health, Qatar University, Doha, Qatar; 3Mental Health Servic
Externí odkaz:
https://doaj.org/article/59a386bda2a1478da96afc348a640f88
Publikováno v:
Неонатологія, хірургія та перинатальна медицина, Vol 13, Iss 4(50) (2023)
Pharmacogenetic testing (PT) is a modern tool in the doctor’s practice, which allows to make the right clinical decision in diffi cult cases, when the expected result of medical measures is not achieved. It is clear that certain metabolic processes
Externí odkaz:
https://doaj.org/article/8f3798da588544dbbe014a7ab2aeba78
Publikováno v:
Frontiers in Genetics, Vol 14 (2023)
Psychotropic medications are typically prescribed in a trial-and-error fashion, and some providers are beginning to utilize pharmacogenetic testing (PGx) as a supplemental prescribing tool in treatment decision making. PGx testing shows potential in
Externí odkaz:
https://doaj.org/article/403be553fb664c82a873eaa10bf7dd72